News Sentiment

CORT sentiment intelligence

Corcept Therapeutics Incorporated news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 90.52 Week of 17 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-1.5% over one week, +13.3% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Corcept Sets July 29 Results Call for 5 p.m. Eastern

Market Reaction

Balanced read

60/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction -1.5% Price digesting
Trend fit Trend active 13.3% over four weeks
Fair value 83.3% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 33
Negative 12

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 9
Market source 8
simplywall.st 7
Motley Fool 3
Investing.com 3
Simply Wall Street 3
TradingView 3
Investing.com Canada 2

Event Lens

What the news is about

Classified themes
Market update 36
Earnings 17
Regulatory and legal 2
Guidance 2
Balance sheet 1
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 59
Investing.com Canada Direct company coverage

Corcept Therapeutics stock hits 52-week high at 95.18 USD By Investing.com

Corcept Therapeutics (CORT) stock has climbed to a new 52-week high of $95.18, showcasing a 152% return over the past six months and a 163% year-to-date gain, reflecting strong investor confidence and strategic advancements. Despite an InvestingPro analysis indicating the stock m

Tone
Positive 72/100
Event
Market update
Published
21 Jul 2026 14:09
Source
Investing.com Canada
Moomoo Direct company coverage

Corcept Therapeutics(CORT.US) Officer Sells US$3.51 Million in Common Stock

Corcept Therapeutics (CORT.US) officer, Gary Charles Robb, sold 100,000 shares of common stock for a total of $3.51 million. The transaction took place on July 16, 2026, and the shares were sold at an average price of $35.1 per share. Following this sale, Robb still directly owns

Tone
Negative 30/100
Event
Market update
Published
18 Jul 2026 05:12
Source
Moomoo
Stock Titan Direct company coverage

Corcept Therapeutics (CORT) CFO sells 40,000 shares and exercises options

Corcept Therapeutics CFO Atabak Mokari exercised options for 40,000 shares and subsequently sold all 40,000 shares on July 15, 2026. The sales were conducted under a Rule 10b5-1 trading plan and involved weighted average prices ranging from $86.7760 to $89.4282 per share. Followi

Tone
Neutral 50/100
Event
Market update
Published
18 Jul 2026 04:39
Source
Stock Titan
Investing.com Direct company coverage

Corcept Therapeutics director Wilson sells $882,985 in common stock

James N. Wilson, a director at Corcept Therapeutics Inc. (NASDAQ: CORT), sold 10,000 shares of the company's common stock for over $882,985 on July 15, 2026. This transaction was part of a pre-arranged 10b5-1 trading plan. The sale occurs while the stock is near its 52-week high

Tone
Negative 39/100
Event
Market update
Published
18 Jul 2026 04:39
Source
Investing.com
Stock Titan Direct company coverage

Corcept Therapeutics (CORT) director logs 10,000-share indirect sale under 10b5-1 plan

Corcept Therapeutics director James N. Wilson, through the James N. Wilson and Pamela D. Wilson Trust, reported an indirect sale of 10,000 shares of common stock on July 15, 2026. The sales were executed under a Rule 10b5-1 trading plan at weighted-average prices ranging from $86

Tone
Negative 39/100
Event
Market update
Published
18 Jul 2026 00:39
Source
Stock Titan
24/7 Wall St. Direct company coverage

Corcept Therapeutics : CORT

This article provides an overview of Corcept Therapeutics (CORT), a biopharmaceutical company focused on treating severe disorders, including Cushing's syndrome with its flagship product Korlym. It highlights the company's robust pipeline, currently in late-stage clinical trials

Tone
Positive 70/100
Event
Market update
Published
09 Jul 2026 17:40
Source
24/7 Wall St.
Simply Wall Street Direct company coverage

Is Corcept Therapeutics (CORT) Fully Valued On Its Russell Index Removal?

Corcept Therapeutics (CORT) was removed from the Russell 1000 Growth Defensive Index and the Russell 1000 Defensive Index, which primarily impacts trading activity and liquidity. The stock has seen significant share price momentum over the past year, with a 31.1% one-year total s

Tone
Negative 40/100
Event
Balance sheet
Published
09 Jul 2026 13:40
Source
Simply Wall Street
Stock Titan Direct company coverage

Corcept (NASDAQ: CORT) CBO reports 600-share stock gift and holdings

Corcept Therapeutics' Chief Business Officer, Gary Charles Robb, reported a gift of 600 shares of common stock on May 27, 2026, with no sale price. Following this transaction, Robb directly holds 25,081 shares, and indirectly holds 49,716 shares through a revocable trust and 12,5

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 00:44
Source
Stock Titan
Investing.com South Africa Direct company coverage

Form 4 Corcept Therapeutics Incorporated For: 8 July By Investing.com

This article from Investing.com announces a Form 4 filing for Corcept Therapeutics Incorporated (CORT) on July 8. The brief update provides the stock symbol and its recent performance (-1.17%), indicating a transactional report relevant to the company. The rest of the content inc

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 23:41
Source
Investing.com South Africa
Stock Titan Direct company coverage

Insider at Corcept (NASDAQ: CORT) sells shares after option exercise

Corcept Therapeutics Chief Development Officer William Guyer exercised stock options for 20,000 shares at $21.65 and simultaneously sold them on the open market at weighted average prices of $93.11 and $93.54. These transactions, totaling $1.86 million, were conducted under a pre

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 23:41
Source
Stock Titan
Investing.com Canada Direct company coverage

Corcept Therapeutics CDO William Guyer sells $1.86m in stock By Investing.com

Corcept Therapeutics' Chief Development Officer, William Guyer, sold 20,000 shares of company stock for approximately $1.86 million, executed under a pre-arranged trading plan. This sale occurred near the stock's 52-week high, with the company also having other recent development

Tone
Negative 34/100
Event
Market update
Published
08 Jul 2026 23:41
Source
Investing.com Canada
Investing.com Nigeria Direct company coverage

Form 144 CORCEPT THERAPEUTICS INC For: 7 July By Investing.com

This article from Investing.com reports on a Form 144 filing for Corcept Therapeutics Inc. (CORT) specifically for July 7th. The article provides the company's stock symbol and a slight negative price change for the day mentioned, indicating a transaction filing relevant to insid

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 13:40
Source
Investing.com Nigeria
Stock Titan Direct company coverage

William Guyer to sell 20,000 CORT shares (NASDAQ: CORT) via option exercise

William Guyer has filed a Form 144 to sell 20,000 shares of Corcept Therapeutics Inc. (NASDAQ: CORT) common stock through a stock option exercise on July 7, 2026. The filing also disclosed three previous sales of 20,000 shares each in April, May, and June of 2026, with proceeds r

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 15:40
Source
Stock Titan
Stock Titan Direct company coverage

Corcept (CORT) executive sells 25K shares after exercising options

Corcept Therapeutics executive Sean Maduck exercised options for 25,000 shares at $8.27 each and subsequently sold all 25,000 shares in open-market transactions at an average price between $87 and $89 per share. These transactions were made under a Rule 10b5-1 trading plan establ

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 21:10
Source
Stock Titan
Investing.com Direct company coverage

Corcept Therapeutics stock hits 52-week high at 91.1 USD

Corcept Therapeutics (CORT) stock recently hit a new 52-week high of $91.10, marking significant appreciation over the past year and year-to-date. This surge has increased the company's market capitalization to $9.68 billion, although InvestingPro analysis suggests the stock is c

Tone
Positive 66/100
Event
Market update
Published
06 Jul 2026 14:10
Source
Investing.com
Simply Wall Street Direct company coverage

Does Corcept’s Exit From Russell Defensive Indexes Reframe Its Risk Profile And Investor Base (CORT)?

Corcept Therapeutics (CORT) was removed from the Russell 1000 Defensive and Growth-Defensive Indexes in late June 2026, which may influence index-tracking investors and shift demand for its stock. This move highlights how sentiment and ownership patterns can change as Corcept pur

Tone
Neutral 50/100
Event
Macro sensitivity
Published
06 Jul 2026 01:10
Source
Simply Wall Street